← Back to Clinical Trials
Recruiting NCT07176416

NCT07176416 Effective Phaco Time and Endothelial Cell Loss When Using Veritas

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07176416
Status Recruiting
Phase
Sponsor Aloha Vision Consultants
Condition Cataract
Study Type OBSERVATIONAL
Enrollment 50 participants
Start Date 2025-10-03
Primary Completion 2026-10-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Veritas Vision System

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 50 participants in total. It began in 2025-10-03 with a primary completion date of 2026-10-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study is a single center, prospective study of cumulative dissipated energy and endothelial cells loss per phacoemulsification procedure after successful cataract surgery. Subjects will be assessed 3 months postoperatively at a single visit. Clinical evaluations will include central corneal thickness, specular microscopy, as well as measurement of visual acuities at distance.

Eligibility Criteria

Inclusion Criteria: * Adult patients undergoing age-related cataract surgery. * Planned use of the Catalys Precision Laser System. * Planned implantation of TECNIS intraocular lenses (IOLs). Exclusion Criteria: • Moderate-severe any disease state (deemed by the surgeon) that could increase risk of complicated cataract surgery (ie, pseudoexfoliation syndrome, zonular dehiscence, history of eye trauma, and prior refractive surgery).

Contact & Investigator

Central Contact

Alana K Dunn

✉ avc.alanad@gmail.com

📞 808-688-6898

Principal Investigator

Carlton Yuen, MD

PRINCIPAL INVESTIGATOR

Aloha Vision Consultants

Frequently Asked Questions

Who can join the NCT07176416 clinical trial?

This trial is open to participants of all sexes, studying Cataract. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07176416 currently recruiting?

Yes, NCT07176416 is actively recruiting participants. Contact the research team at avc.alanad@gmail.com for enrollment information.

Where is the NCT07176416 trial being conducted?

This trial is being conducted at ‘Aiea, United States.

Who is sponsoring the NCT07176416 clinical trial?

NCT07176416 is sponsored by Aloha Vision Consultants. The principal investigator is Carlton Yuen, MD at Aloha Vision Consultants. The trial plans to enroll 50 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology